Hormonal Effects of Single Gonadotropin-Releasing Hormone Antagonist Doses in Men*

Publisher Website
Google Scholar
Abstract
To assess its gonadotropin-inhibiting potency in man, three different doses of a GnRH antagonist ([Ac-D2-Nal1,d4-Cl-Phe2, d3-Pal3, Arg5,d4-p-methoxybenzoyl-2-amino butyric acid6,d-Ala10]GnRH; Nal-Glu GnRH antagonist) were given to six normal men. Single sc doses of 0.5, 1.5, and 5.0 mg Nal-Glu GnRH decreased mean serum immunoactive LH (iLH) to 45.0 ± 5.7% (±SE), 37.0 ± 4.9%, and 31.3 ± 4.2% of baseline, respectively. Maximal suppression occurred between 4 and 8 h after drug injection. Serum bioassayable LH concentrations significantly diminished 8 h after injection of 1.5 and 5.0 mg GnRH antagonist, but not after the 0.5-mg dose. Mean serum testosterone (T) fell to 39.8 ± 5.0%, 32.1 ± 4.9%, and 20.7 ± 4.4% of baseline, respectively, after the 0.5-, 1.5-, and 5.0-mg doses. The decreases in serum iLH and testosterone (T) were more sustained after the higher doses; serum iLH and T were significantly suppressed 24 h after administration of the 5.0-mg dose. Twenty-four-hour integrated serum iLH and T concentrations decreased in a dose-dependent manner. However, basal and 24-h integrated serum FSH concentrations were not significantly affected by the drug. No adverse systemic side-effects occurred. Thus, the Nal-Glu GnRH antagonist effectively decreases serum LH and T concentrations in a dose- and timedependent manner, and it, therefore, has potential as a male contraceptive.

This publication has 16 references indexed in Scilit: